On Nov 09, major Wall Street analysts update their ratings for $Arcellx (ACLX.US)$, with price targets ranging from $105 to $122.
Morgan Stanley analyst Judah Frommer maintains with a buy rating, and adjusts the target price from $106 to $111.
Evercore analyst Cory Kasimov maintains with a buy rating, and maintains the target price at $120.
Needham analyst Gil Blum maintains with a buy rating, and adjusts the target price from $96 to $105.
Stifel analyst Benjamin Burnett maintains with a buy rating, and maintains the target price at $122.
William Blair analyst Sami Corwin maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Arcellx (ACLX.US)$'s main analysts recently are as follows:
The assessment of Arcellx's anito-cel success probabilities has been revised upward after reviewing initial data from the iMMagine-1 Phase 2 trial in patients with relapsed/refractory multiple myeloma. Analysts perceive a significant opportunity for market share capture by anito-cel, initially among patients treated in later stages, and potentially extending to those in earlier stages if the current clinical outcomes are sustained.
The analyst noted that recent abstracts including initial Phase 2 data and additional Phase 1 follow-up data reinforce the competitive positioning and regulatory progress of pivotal-stage anito-cel in the treatment of multiple myeloma. Despite a recent decline in share price, which is viewed as a 'sell the news' reaction following a significant rise due to abstract anticipation, the analyst's perspective is that anito-cel is poised to secure a more formidable peak market share with increased probability of success.
The firm expressed a growing positive stance regarding the updated clinical data. The release of ASH abstracts online, which included initial data from the IMMagine-1 study, contributed to this view.
Here are the latest investment ratings and price targets for $Arcellx (ACLX.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
